sb 203580 has been researched along with gliclazide in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (gliclazide) | Trials (gliclazide) | Recent Studies (post-2010) (gliclazide) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 997 | 214 | 308 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dey, CS; Kumar, N | 1 |
1 other study(ies) available for sb 203580 and gliclazide
| Article | Year |
|---|---|
Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells.
Topics: Animals; Cell Line; Deoxyglucose; Enzyme Inhibitors; Gliclazide; Hypoglycemic Agents; Imidazoles; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Muscle, Skeletal; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Pyridines; Receptor, Insulin; Signal Transduction; Tyrosine | 2002 |